Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

A landmark new CDC study dubbed TDF2 — along with a separate trial released July 13, 2011 — provide the first evidence that a daily oral dose of antiretroviral drugs used to treat HIV infection can reduce HIV acquisition among uninfected individuals exposed to the virus through heterosexual sex, the Centers for Disease Control & Prevention reports.

CDC trial: HIV PrEP works for heterosexuals